Chemically Diverse S. mansoni HDAC8 Inhibitors Reduce Viability in Worm Larval and Adult Stages

ChemMedChem. 2023 Feb 1;18(3):e202200510. doi: 10.1002/cmdc.202200510. Epub 2022 Nov 8.

Abstract

Schistosoma mansoni HDAC8 is a reliable target to fight schistosomiasis, and several inhibitors have been reported in the literature up to now. Nevertheless, only a few displayed selectivity over the human deacetylases and some exhibited very low or no activity against parasite larvae and/or adult worms. We report here the in vitro enzyme and biological activity of a small library of HDAC inhibitors from our lab, in many cases exhibiting submicromolar/nanomolar potency against smHDAC8 and diverse degrees of selectivity over hHDAC1 and/or hHDAC6. Such compounds were tested against schistosomula, and a selection of them against the adult forms of S. mansoni, to detect their effect on viability. Some of them showed the highest viability reduction for the larval stage with IC50 values around 1 μM and/or displayed ∼40-50 % activity in adult worms at 10 μM, joined to moderate to no toxicity in human fibroblast MRC-5 cells.

Keywords: S. mansoni; epigenetic drugs; histone deacetylase inhibitors; neglected parasitic diseases; newly transformed schistosomula.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Histone Deacetylase Inhibitors* / pharmacology
  • Histone Deacetylase Inhibitors* / therapeutic use
  • Histone Deacetylases* / genetics
  • Humans
  • Larva / drug effects
  • Repressor Proteins / antagonists & inhibitors
  • Repressor Proteins / genetics
  • Schistosoma mansoni* / drug effects
  • Schistosoma mansoni* / genetics
  • Schistosomiasis* / drug therapy
  • Schistosomiasis* / genetics

Substances

  • HDAC8 protein, human
  • Histone Deacetylase Inhibitors
  • Histone Deacetylases
  • Repressor Proteins